Regulation
Guardant ordered to pay $245m in DNA sequencing patent dispute
Guardant Health was ordered to pay $245 million in a patent dispute over DNA sequencing technology. The ruling includes a 6% ongoing royalties obligation that the company plans to appeal. The case concerns intellectual property rights related to sequencing methods used in the company's diagnostic platforms.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network